Title

M.S. in Biomedical Innovation and Development – Advanced Therapeutics

Subhead
Lead the Next Wave of Medical Breakthroughs in Cell, Gene, and Regenerative Therapies
Sections
Program Highlights

The MSBID-AT program at Emory University is a full-time, 12-month professional master’s degree designed to prepare students for impactful careers in the rapidly growing field of advanced therapeutics. Unlike traditional programs in drug discovery or vaccine development, MSBID-AT focuses on emerging industries such as cell therapy, gene therapy, tissue engineering, and regenerative medicine. Students gain hands-on experience at the intersection of science, healthcare, and business—ready to translate innovation from lab to bedside.

TendoNova's Ocelot device, a handheld tool to perform mechanical fragmentation and debridement of targeted tissues, a common procedure for athletes and others suffering from tendon pain disorders like tennis elbow, plantar fasciitis, and jumper’s knee. (Image Courtesy: TendoNova)

Program Details

Curriculum

The MSBID-AT curriculum is designed to cover the full lifecycle of advanced therapeutic development—from identifying unmet clinical needs to commercialization. Students work in teams to identify a real-world clinical challenge, propose a therapeutic solution, and develop a commercialization strategy including regulatory and reimbursement pathways.

Fall Term (11 credit hours total)
Understanding the Global Therapeutics Market2 credit hours
Introduction to Emerging Technologies in Advanced Therapeutics2 credit hours
Preclinical Product and Process Development3 credit hours
Global Clinical Strategy and Clinical Operations2 credit hours
Medical Ethics, Medical Affairs, and Clinical Communication2 credit hours
  
Spring Term (10 credit hours total)
Clinical and Commercial Scale Manufacturing Strategies3 credit hours
Regulatory and Quality Affairs3 credit hours
Project Management, Corporate Communication, and Organization in Biotech2 credit hours
MSBID-AT Team Project I2 credit hours
  
Summer Term (9 credit hours total)
Corporate Marketing, Intellectual Property and Legal Considerations3 credit hours
Financing and Reimbursement in Biotech3 credit hours
MSBID-AT Team Project II3 credit hours
Total Credit Hours30 credit hours

Course Descriptions

Meet the Instructors
The MSBID-AT program is taught by leading experts in biomedical engineering, entrepreneurship, and clinical innovation.
  • Angela Gill Nelms – Managing Director, Biolocity; biotech entrepreneur and commercialization strategist
  • Samir Patel, Ph.D. – Co-founder & CEO, Moonlight Therapeutics; expert in drug delivery and startup leadership
  • Phillip J. Santangelo, Ph.D. – Professor of Biomedical Engineering; pioneer in nucleic acid-based therapies
  • Abbey Wojtowicz, Ph.D. – Medical Director in gastroenterology; specialist in strategic scientific communications
Career Possibilities

Graduates are equipped for high-impact roles, including:

  • Product Development and R&D
  • Regenerative Medicine Scientist
  • Biologics Process Development Specialist
  • Regulatory Affairs Scientist
  • Clinical Research Scientist
  • Drug Delivery Design Engineer
  • Biotechnology Startup

Alumni pursue careers in leading biotech and pharmaceutical companies or continue in translational research and innovation

Clean rooms made for an interesting backdrop to the BME Career Fair.

We're here to help

Interested in learning more about the MSBID-AT program or wondering if it’s the right fit for your career goals?

We’re here to answer your questions and help you take the next step.

Program Contact:

Carolyn Yeago
Director of Graduate Study
cyeago@emory.edu

Featured News